Jubilant Life#39;s performance would be driven by market share gains in key radiopharmaceutical products, a ramp-up in CMO business, capacity additions in finished dosages Life Science Chemical segment and opportunities from the supply of ethanol to government, IDBI Capital saidTroubles brew at this pharmacy but analysts see up to 100% return in a year
Jubilant Life#39;s performance would be driven by market share gains in key radiopharmaceutical products, a ramp-up in CMO business, capacity additions in finished dosages Life Science Chemical segment and opportunities from the supply of ethanol to government, IDBI Capital said
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The bank plans to raise up to Rs 500 crore by issue of equity shares to qualified institutional buyers through qualified institutional plac...
-
In July, HCL Technologies had announced a Rs 4,000 crore buyback programme for FY19 at a price of Rs 1,100 per equity share.
No comments:
Post a Comment